Indication

Prevention of chemotherapy-induced mucositis

Prevention of chemotherapy-induced mucositis refers to therapeutic strategies aimed at averting or diminishing the severity of inflammatory and ulcerative mucosal injury caused by cytotoxic antineoplastic agents. Read more about Prevention of chemotherapy-induced mucositis

1 drugs 1 manufacturers

Drugs that treat it

Common Prevention of chemotherapy-induced mucositis therapies.

Showing 1–1 of 1 drugs

Sort

KEPIVANCE (palifermin)

TREATMENT INDUCED MUCOSITIS AGENTS·PREVENTION OF CHEMOTHERAPY-INDUCED MUCOSITIS·+1

BIOVITRUM

Filter & compare in the drug finder →Opens the drug finder with Prevention of chemotherapy-induced mucositis preselected.

News & literature

Coming soon

Related codes

Coming soon

About Prevention of chemotherapy-induced mucositis.

This complication primarily compromises the epithelial lining of the gastrointestinal tract, most frequently presenting as oral or intestinal mucositis in cancer patients undergoing moderate-to-high-dose or myeloablative chemotherapy regimens.

Pathophysiologically, cytotoxic exposure disrupts rapid epithelial cell turnover, triggers reactive oxygen species generation, and activates proinflammatory signaling cascades, leading to tissue atrophy, painful ulcerations, and loss of mucosal barrier integrity.

Clinically, preventing this damage reduces severe mucosal pain, secondary systemic infections, compromised nutritional intake, and subsequent antineoplastic dose reductions or delays.

nih.gov
Prevention of chemotherapy-induced mucositis refers to therapeutic strategies aimed at averting or diminishing the severity of inflammatory and ulcerative mucosal injury caused by cytotoxic antineoplastic agents
nih.gov
Prevention of chemotherapy-induced mucositis refers to therapeutic strategies aimed at averting or diminishing the severity of inflammatory and ulcerative mucosal injury caused by cytotoxic antineoplastic agents Pathophysiologically, cytotoxic exposure disrupts rapid epithelial cell turnover, triggers reactive oxygen species generation, and activates proinflammatory signaling cascades, leading to tissue atrophy, painful ulcerations, and loss of mucosal barrier integrity
nih.gov
This complication primarily compromises the epithelial lining of the gastrointestinal tract, most frequently presenting as oral or intestinal mucositis in cancer patients undergoing moderate-to-high-dose or myeloablative chemotherapy regimens Clinically, preventing this damage reduces severe mucosal pain, secondary systemic infections, compromised nutritional intake, and subsequent antineoplastic dose reductions or delays
nih.gov
This complication primarily compromises the epithelial lining of the gastrointestinal tract, most frequently presenting as oral or intestinal mucositis in cancer patients undergoing moderate-to-high-dose or myeloablative chemotherapy regimens
nih.gov
Pathophysiologically, cytotoxic exposure disrupts rapid epithelial cell turnover, triggers reactive oxygen species generation, and activates proinflammatory signaling cascades, leading to tissue atrophy, painful ulcerations, and loss of mucosal barrier integrity
nih.gov
Pathophysiologically, cytotoxic exposure disrupts rapid epithelial cell turnover, triggers reactive oxygen species generation, and activates proinflammatory signaling cascades, leading to tissue atrophy, painful ulcerations, and loss of mucosal barrier integrity
nih.gov
Clinically, preventing this damage reduces severe mucosal pain, secondary systemic infections, compromised nutritional intake, and subsequent antineoplastic dose reductions or delays

Personalize your experience

Follow Prevention of chemotherapy-induced mucositis and get updates as they land.

Create a free account

Already a member? Sign in

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it